Many COVID-19 patients are participating in trials and studies evaluating whether heart and anti-platelet drugs are effective treatments, according to The Wall Street Journal. Some researchers argue that COVID-19 is a vascular disease as well as a respiratory one and have been testing cardiovascular drugs' ability to reduce inflammation and fluid in the lungs. Several trials are testing losartan a high blood pressure drug that could block the angiotensin receptor that causes inflammation and fluid in the lungs. Becker's HospitalReview
Wednesday, June 3, 2020
Researchers testing several heart, anti-platelet drugs for COVID-19 patients
Many COVID-19 patients are participating in trials and studies evaluating whether heart and anti-platelet drugs are effective treatments, according to The Wall Street Journal. Some researchers argue that COVID-19 is a vascular disease as well as a respiratory one and have been testing cardiovascular drugs' ability to reduce inflammation and fluid in the lungs. Several trials are testing losartan a high blood pressure drug that could block the angiotensin receptor that causes inflammation and fluid in the lungs. Becker's HospitalReview
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment